(Q50524262)

14 March 2018

title

Ventricular rate adaptation: a novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds. (English)

1 reference

14 March 2018

author name string

Jonathon R Green

1

1 reference

14 March 2018

Gilbert J Diaz

2

1 reference

14 March 2018

James T Limberis

3

1 reference

14 March 2018

Kathryn A Houseman

4

1 reference

14 March 2018

Zhi Su

5

1 reference

14 March 2018

Ruth L Martin

6

1 reference

14 March 2018

Bryan F Cox

7

1 reference

14 March 2018

Stan Kantor

8

1 reference

14 March 2018

Gary A Gintant

9

1 reference

14 March 2018

publication date

2 April 2011

1 reference

14 March 2018

Journal of Pharmacological and Toxicological Methods

published in

1 reference

14 March 2018

volume

64

1 reference

14 March 2018

issue

1

1 reference

14 March 2018

page(s)

68-73

1 reference

14 March 2018

Fluoxetine and ventricular torsade — is there a link?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Giant T–U Waves Precede Torsades de Pointes in Long QT Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Benchmarking safety pharmacology regulatory packages and best practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

QT PRODACT: evaluation of the potential of compounds to cause QT interval prolongation by action potential assays using guinea-pig papillary muscles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

The link between repolarisation alternans and ventricular arrhythmia: does the cellular phenomenon extend to the clinical problem?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Drug-induced prolongation of the QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

A novel secretagogue increases cardiac contractility by enhancement of L-type Ca2+ current

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Emerging clinical role of ranolazine in the management of angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Fluoxetine (Prozac) as a cause of QT prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Early clinical development: evaluation of drug-induced torsades de pointes risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.03.005

10.1016/J.VASCN.2011.03.005

7 January 2021

Identifiers

DOI

1 reference

14 March 2018

1 reference

14 March 2018